Therapeutic strategies in somatotroph adenomas with extrasellar extension: Role of the medical approach, a consensus study of the French Acromegaly Registry;Stratégies thérapeutiques dans les adénomes somatotropes avec extension extrasellaire: Place du traitement médical - Étude Consensus du Répertoire Français de l'Acromégalie

Annales d'Endocrinologie

Volumn 64, Issue 6, 2003, Pages 434-441

  Jaquet, Ph ^a   Cortet Rudelli, Ch ^b   Sassolas, G ^c   Morange Ramos, I ^a   Chanson, P ^d   Brue, Th ^a   Andrieu, J M ^a   Beckers, A ^a   Bertherat, J ^a   Borson Chazot, F ^a   Brassier, G ^a   Caron, Ph ^a   Cogne, M ^a   Cottier, J Ph ^a   Delemer, B ^a   Dufour, H ^a   Enjalbert, A ^a   Figarella Branger, D ^a   Gaillard, R ^a   Gueydan, M ^a   Jan, M ^a   Kuhn, J M ^a   Raingeard, I ^a   Regis, J ^a   Roger, P ^a   Rohmer, V ^a   Sadoul, J L ^a   Saveanu, A ^a   Tabarin, A ^a   Travers, N ^a   Trouillas, J ^a   more..

^a TIMONE HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Serv de Cardiologie Pediat   (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

Acromegaly; Cavernous sinus; Growth hormone; Lanreotide; National registry; Octreotide; Pituitary; Radiosurgery; Somatostatin analogs; Surgery

Indexed keywords

ANGIOPEPTIN; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADENOMA; ADULT; AGED; CAVERNOUS SINUS; CONSENSUS; DIAGNOSTIC IMAGING; FEMALE; FRANCE; GROWTH HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOSURGERY; REGISTER; REMISSION; REVIEW; SELLA TURCICA; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; AGED; CAVERNOUS SINUS; COMBINED MODALITY THERAPY; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPOPHYSECTOMY; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; OCTREOTIDE; PITUITARY NEOPLASMS; RADIOTHERAPY, ADJUVANT; REGISTRIES; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 10744224343     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998; 83: 3411-3418.
2. Ahmed S, Elsheikh M, Page RCI, Adams CBT, Wass JAH. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical expericence. Clin Endocrinol 1999; 50: 561-567.
3. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002; 56(1): 65-71.
4. Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002; 87: 4142-4146.
5. Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000; 85(11): 4099-103.
6. Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, and Bertherat J. Hormonal and Metabolic Effects of Radiotherapy in Acromegaly: Long-Term Results in 128 Patients Followed in a Single Center. J Clin Endocrinol Metab 2000 85: 3779-3785.
7. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Quartely J Medecine 1993; 86: 293-299.
8. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, Mc Connell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JAH, Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumour size. J Clin Endocrinol Metab 2002; 87: 4554-4563.
9. Bonneville JF, Cattin F, Racle A, Bouchareb M, Boulard D, Potelon P. Dynamic CT of the laterosellar extradural venous spaces. Am J Neuroradiol 1989; 10: 535-42.
10. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002; 87: 99-104.
11. Chanson P, Leselbaum A, Blumberg J, Schaison G. Efficacy and tolerability of the long-acting somatostatin analogue lanreotide in acromegaly. A 12-month multicenter study of 58 acromegaly patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary 2000; 2: 269-276.
12. Colao A, Ferone F, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001; 86: 2779-2786.
13. Cottier JP, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M, Herbreteau D. MR imaging of cavernous sinus invasion by pituitary adenoma. Radiology 2000; 215: 463-69.
14. Gittoes NJL, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly - the experience of a dedicated pituitary surgeon. Quartely J Medicine 1999; 92: 741-745.
15. Giustina A, Barkan A, Casanueva F, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000; 85: 526-529.
16. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33: 610-8.
17. Kreutzer J, Vance ML, Lopes MBS, Laws ER. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001; 86: 4072-4077.
18. Lancranjan I, Brew Atkinson A. and the Sandostatin LAR Group. Results of a European multicenter study with sandostatin LAR in acromegaly patients. Pituitary 1999; 1: 105-114.
19. Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER The long term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transphenoidal surgery. J Neurosurg 2002, 96: 195-208.
20. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Moltich ME, Gagel R, Sheeler L, Cook L, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3034-3040.
21. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE and the United Kingdom Acromegaly Study Group. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998; 83: 2730-2734.
22. Scotti G, Yu CY, Dillon WP, Norman D, Colombo N, Newton TH. MR imaging of cavernous sinus involvement by pituitary adenomas. Am J Neuroradiol 1988; 9: 657-64.
23. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JAH. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 1996; 45: 407-413.
24. Sheppard M. Primary medical therapy for acromegaly. Clin Endocrinol 2003; 58: 387-399.
25. Swearingen B, Barker FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, Moyaeri N, Black PM, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3419-3426.
26. Trouillas J, Sassolas G, Guigard MP, Fonlupt P, Ansaneli-Naves L, Perrin G. Relationship between pathological diagnosis and clinical parameters in acromegaly. Metabolism 1996; 45: 53-56.
27. Van der Lely A, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hacker S, Zib KA, Davis RJ, Scarlett JA, Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 385: 1754-1759.
28. Van der Lely A J, de Herder W W. The Role of Radiotherapy in Acromegaly. J Clin Endocrinol Metab 1997; 82: 3185-3186.
29. Wood P. Growth hormone: its measurement and the need for assay harmonization. Ann Clin Biochem 2001; 38: 471-482.